Journal Article

CAR-T Cells in the Treatment of Ovarian Cancer: A Promising Cell Therapy

Zhang, Xi-Wen, Wu, Yi-Shi, Cui, Man-Hua, Xu, Tian-Min

2023

Overview

Ovarian cancer (OC) is among the most common gynecologic malignancies with a poor prognosis and a high mortality rate. Most patients are diagnosed at an advanced stage (stage III or IV), with 5-year survival rates ranging from 25% to 47% worldwide. Surgical resection and first-line chemotherapy are the main treatment modalities for OC. However, patients usually relapse within a few years of initial treatment due to resistance to chemotherapy. Cell-based therapies, particularly adoptive T-cell therapy and chimeric antigen receptor T (CAR-T) cell therapy, represent an alternative immunotherapy approach with great potential for hematologic malignancies. However, the use of CAR-T-cell therapy for the treatment of OC is still associated with several difficulties. In this review, we comprehensively discuss recent innovations in CAR-T-cell engineering to improve clinical efficacy, as well as strategies to overcome the limitations of CAR-T-cell therapy in OC.

• Publisher: MDPI AG,MDPI
• Subject: Antigens / Apoptosis / Blood cancer / Cancer therapies / CAR / CAR-T / Care and treatment / Cell therapy / Cell- and Tissue-Based Therapy / Cells / Chemotherapy / Chimeric antigen receptors / Cytokines / Female / Gene amplification / Glycoproteins / Humans / Immunotherapy / Kinases / Lymphocytes / Lymphocytes T / Malignancy / Medical prognosis / Medical research / Monoclonal antibodies / Ovarian cancer / Ovarian Neoplasms - therapy / Patients / Receptors, Antigen, T-Cell / Receptors, Chimeric Antigen - genetics / Review / T-Lymphocytes / Tumors